Shopping Cart 0
Cart Subtotal
AED 0

MagForce AG (MF6) - Product Pipeline Analysis, 2019 Update

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 2753

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 5505

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 8258

Details

Summary

MagForce AG (MagForce) is a medical device company that offers nanotechnology-based therapy for cancer treatment. The company's products include NanoActivator, NanoTherm, NanoPlan and NanoTherm Therapy. Its NanoActivator creates a magnetic field that can be used to treat tumors in all areas of the body. MagForce's NanoTherm is a liquid that reacts to the presence of magnetic field. The company's NanoPlan uses the bioheat transfer equation to help the physician in charge estimate treatment temperatures and the magnetic field strength. Its products are used in the treatment of prostate cancer, pancreatic cancer, esophageal cancer and glioblastoma. MagForce is headquartered in Berlin, Germany.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company MagForce AG

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

MagForce AG Company Overview

MagForce AG Company Snapshot

MagForce AG Pipeline Products and Ongoing Clinical Trials Overview

MagForce AG-Pipeline Analysis Overview

MagForce AG-Key Facts

MagForce AG-Major Products and Services

MagForce AG Pipeline Products by Development Stage

MagForce AG Ongoing Clinical Trials by Trial Status

MagForce AG Pipeline Products Overview

NanoTherm-Brain Cancer

NanoTherm-Brain Cancer Product Overview

NanoTherm-Gastrointestinal Cancer

NanoTherm-Gastrointestinal Cancer Product Overview

NanoTherm-Pancreatic Carcinoma

NanoTherm-Pancreatic Carcinoma Product Overview

NanoTherm-Prostate Carcinoma

NanoTherm-Prostate Carcinoma Product Overview

NanoTherm-Prostate Carcinoma Clinical Trial

NanoTherm-Recurrent Glioblastoma

NanoTherm-Recurrent Glioblastoma Product Overview

Next-Generation Nanotherm

Next-Generation Nanotherm Product Overview

MagForce AG-Key Competitors

MagForce AG-Key Employees

MagForce AG-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Recent Developments

MagForce AG, Recent Developments

Oct 31, 2019: MagForce publishes financial results for the first half of 2019 and operative highlights

Jun 20, 2019: MagForce publishes financial results for the year 2018 and operative highlights

Apr 04, 2019: MagForce: Inauguration ceremony marks official opening of new NanoTherm Treatment Center at Independent Public Clinical Hospital No. 4 in Lublin, Poland

Mar 21, 2019: MagForce successfully completes installation of mobile NanoTherm treatment center for brain tumors in Poland

Feb 06, 2019: MagForce: Newly launched 'NanoTherm Therapy School' kicks off with successful first training session

Oct 23, 2018: MagForce publishes financial results for the first half of 2018 and operative highlights

Jul 02, 2018: MagForce Announces Enrollment of First Patient in its Pivotal, Three-Stage, Single-Arm Study of Focal Ablation of Prostate Cancer with NanoTherm Therapy

Jun 14, 2018: MagForce Co-Sponsors the University Hospital of Munster's Annual Brain Cancer Patient Event

Jun 12, 2018: MagForce Announces Collaboration Agreement for NanoTherm Therapy with Independent Public Clinical Hospital No. 4, Lublin, Poland

Jun 04, 2018: MagForce to host Lunch Symposium about Local Therapies for Malignant Gliomas at the 2018 meeting of the German Society of Neurosurgery (DGNC)

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

MagForce AG Pipeline Products by Equipment Type

MagForce AG Pipeline Products by Development Stage

MagForce AG Ongoing Clinical Trials by Trial Status


List Of Table

List of Tables

MagForce AG Pipeline Products and Ongoing Clinical Trials Overview

MagForce AG Pipeline Products by Equipment Type

MagForce AG Pipeline Products by Indication

MagForce AG Ongoing Clinical Trials by Trial Status

MagForce AG, Key Facts

MagForce AG, Major Products and Services

MagForce AG Number of Pipeline Products by Development Stage

MagForce AG Pipeline Products Summary by Development Stage

MagForce AG Ongoing Clinical Trials by Trial Status

MagForce AG Ongoing Clinical Trials Summary

NanoTherm-Brain Cancer-Product Status

NanoTherm-Brain Cancer-Product Description

NanoTherm-Gastrointestinal Cancer-Product Status

NanoTherm-Gastrointestinal Cancer-Product Description

NanoTherm-Pancreatic Carcinoma-Product Status

NanoTherm-Pancreatic Carcinoma-Product Description

NanoTherm-Prostate Carcinoma-Product Status

NanoTherm-Prostate Carcinoma-Product Description

NanoTherm-Prostate Carcinoma-An Investigational Device Exemption, Phase III Study of NanoTherm therapy as Focal Ablation Treatment for Intermediate Risk Prostate Cancer

NanoTherm-Recurrent Glioblastoma-Product Status

NanoTherm-Recurrent Glioblastoma-Product Description

Next-Generation Nanotherm-Product Status

Next-Generation Nanotherm-Product Description

MagForce AG, Key Employees

MagForce AG, Other Locations

MagForce AG, Subsidiaries

Glossary

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

MagForce AG, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies


Companies

Pulsion Medical Systems SE

German Cancer Research Center

Dragerwerk AG & Co. KGaA.

Curetis NV

Company Profile

Company Profile Title

Summary

MagForce AG (MagForce) is a medical device company that offers nanotechnology-based therapy for cancer treatment. The company's products include NanoActivator, NanoTherm, NanoPlan and NanoTherm Therapy. Its NanoActivator creates a magnetic field that can be used to treat tumors in all areas of the body. MagForce's NanoTherm is a liquid that reacts to the presence of magnetic field. The company's NanoPlan uses the bioheat transfer equation to help the physician in charge estimate treatment temperatures and the magnetic field strength. Its products are used in the treatment of prostate cancer, pancreatic cancer, esophageal cancer and glioblastoma. MagForce is headquartered in Berlin, Germany.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company MagForce AG

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

MagForce AG Company Overview

MagForce AG Company Snapshot

MagForce AG Pipeline Products and Ongoing Clinical Trials Overview

MagForce AG-Pipeline Analysis Overview

MagForce AG-Key Facts

MagForce AG-Major Products and Services

MagForce AG Pipeline Products by Development Stage

MagForce AG Ongoing Clinical Trials by Trial Status

MagForce AG Pipeline Products Overview

NanoTherm-Brain Cancer

NanoTherm-Brain Cancer Product Overview

NanoTherm-Gastrointestinal Cancer

NanoTherm-Gastrointestinal Cancer Product Overview

NanoTherm-Pancreatic Carcinoma

NanoTherm-Pancreatic Carcinoma Product Overview

NanoTherm-Prostate Carcinoma

NanoTherm-Prostate Carcinoma Product Overview

NanoTherm-Prostate Carcinoma Clinical Trial

NanoTherm-Recurrent Glioblastoma

NanoTherm-Recurrent Glioblastoma Product Overview

Next-Generation Nanotherm

Next-Generation Nanotherm Product Overview

MagForce AG-Key Competitors

MagForce AG-Key Employees

MagForce AG-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Recent Developments

MagForce AG, Recent Developments

Oct 31, 2019: MagForce publishes financial results for the first half of 2019 and operative highlights

Jun 20, 2019: MagForce publishes financial results for the year 2018 and operative highlights

Apr 04, 2019: MagForce: Inauguration ceremony marks official opening of new NanoTherm Treatment Center at Independent Public Clinical Hospital No. 4 in Lublin, Poland

Mar 21, 2019: MagForce successfully completes installation of mobile NanoTherm treatment center for brain tumors in Poland

Feb 06, 2019: MagForce: Newly launched 'NanoTherm Therapy School' kicks off with successful first training session

Oct 23, 2018: MagForce publishes financial results for the first half of 2018 and operative highlights

Jul 02, 2018: MagForce Announces Enrollment of First Patient in its Pivotal, Three-Stage, Single-Arm Study of Focal Ablation of Prostate Cancer with NanoTherm Therapy

Jun 14, 2018: MagForce Co-Sponsors the University Hospital of Munster's Annual Brain Cancer Patient Event

Jun 12, 2018: MagForce Announces Collaboration Agreement for NanoTherm Therapy with Independent Public Clinical Hospital No. 4, Lublin, Poland

Jun 04, 2018: MagForce to host Lunch Symposium about Local Therapies for Malignant Gliomas at the 2018 meeting of the German Society of Neurosurgery (DGNC)

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

MagForce AG Pipeline Products by Equipment Type

MagForce AG Pipeline Products by Development Stage

MagForce AG Ongoing Clinical Trials by Trial Status


List Of Table

List of Tables

MagForce AG Pipeline Products and Ongoing Clinical Trials Overview

MagForce AG Pipeline Products by Equipment Type

MagForce AG Pipeline Products by Indication

MagForce AG Ongoing Clinical Trials by Trial Status

MagForce AG, Key Facts

MagForce AG, Major Products and Services

MagForce AG Number of Pipeline Products by Development Stage

MagForce AG Pipeline Products Summary by Development Stage

MagForce AG Ongoing Clinical Trials by Trial Status

MagForce AG Ongoing Clinical Trials Summary

NanoTherm-Brain Cancer-Product Status

NanoTherm-Brain Cancer-Product Description

NanoTherm-Gastrointestinal Cancer-Product Status

NanoTherm-Gastrointestinal Cancer-Product Description

NanoTherm-Pancreatic Carcinoma-Product Status

NanoTherm-Pancreatic Carcinoma-Product Description

NanoTherm-Prostate Carcinoma-Product Status

NanoTherm-Prostate Carcinoma-Product Description

NanoTherm-Prostate Carcinoma-An Investigational Device Exemption, Phase III Study of NanoTherm therapy as Focal Ablation Treatment for Intermediate Risk Prostate Cancer

NanoTherm-Recurrent Glioblastoma-Product Status

NanoTherm-Recurrent Glioblastoma-Product Description

Next-Generation Nanotherm-Product Status

Next-Generation Nanotherm-Product Description

MagForce AG, Key Employees

MagForce AG, Other Locations

MagForce AG, Subsidiaries

Glossary

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

MagForce AG, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies


Companies

Pulsion Medical Systems SE

German Cancer Research Center

Dragerwerk AG & Co. KGaA.

Curetis NV